1189811-71-9

Basic information

• Product Name: 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid
• Synonyms: 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid
• CAS NO: 1189811-71-9
• Molecular Weight: 504.006
• Mol File: 1189811-71-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid(1189811-71-9)
• EPA Substance Registry System: 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetic acid(1189811-71-9)

Safety Data

• Hazardous Substances Data: 1189811-71-9(Hazardous Substances Data)

Upstream product

• 170638-88-7 4-(3-bromophenoxy)butanoic acid 
• 141106-23-2 8-bromo-3,4-dihydrobenzo[b]oxepin-5(2H)-one 
• 150529-73-0 methyl 2-(3-bromophenyl)acetatee 
• 1878-67-7 3-Bromophenylacetic acid 
• 591-20-8 3-Bromophenol 
• 1189816-36-1 8-bromo-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carbonyl chloride 
• 1189815-77-7 8-bromo-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxylic acid 
• 1189810-76-1 8-bromo-N-(2-chlorophenyl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 478375-42-7 methyl 2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate 
• 1189815-76-6 methyl 8-bromo-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxylate 
• 157245-84-6 ethyl 4-(3-bromophenoxy)butanoate 
• 1189811-75-3 methyl 2-(3-(2-((2-chlorophenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepin-8-yl)phenyl)acetate 

Relevant articles and documents

Rational design of phosphoinositide 3-kinase inhibitors that exhibit selectivity over the phosphoinositide 3-kinase isoform

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.